Study Reveals Alarming Effects of Stopping GLP-1 Weight Loss Drugs

Recent research highlights concerning effects for individuals who discontinue the use of Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, including popular treatments like Wegovy and Ozempic. While these medications have demonstrated notable success in aiding weight loss and enhancing overall health, a new study conducted by the University of Oxford sheds light on the challenges faced by patients once they stop their monthly injections.

The study, which reviewed 37 existing weight loss medication trials involving over 9,000 participants, reveals a troubling trend: individuals who ceased taking GLP-1 weight-loss medications regained weight at a rate four times faster than those who engaged in alternative behavioral programs, such as diet and exercise. On average, participants returned to their pre-treatment weight just 1.7 years after stopping the medication.

Many former users have reported a resurgence of intense hunger shortly after discontinuing the drugs. Tanya Hall, a participant who has experienced this firsthand, described her feelings to the BBC, stating, “It was like something opened up in my mind and said: ‘Eat everything, go on, you deserve it because you haven’t eaten anything for so long.’” She added that she felt “completely horrified” by her food intake after only a few days without the medication.

The findings from the Oxford research team indicate that the secondary health benefits of GLP-1 drugs also diminish rapidly. Health markers, including blood pressure and cholesterol levels, reverted to their original states within an average of 1.4 years after stopping treatment. The researchers noted, “This review found that cessation of weight management medications is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers.”

The implications of these findings are significant. Senior author and associate professor at Oxford, Dimitrios Koutoukidis, emphasized that the drugs themselves do not create lasting lifestyle changes. He explained, “This faster regain could be because people using drugs don’t need to consciously practice changing their diet to lose weight, so when they stop taking the medication, they might not have developed the practical strategies that could help them keep it off.”

The study calls for a more cautious approach to the use of GLP-1 medications. Lead author and research scientist at the University of Oxford, Sam West, stated, “These medicines are transforming obesity treatment and can achieve important weight loss. However, our research shows that people tend to regain weight rapidly after stopping — faster than we see with behavioral programs.”

Despite these concerns, West clarified that the efficacy of GLP-1 drugs remains significant. He noted, “This isn’t a failing of the medicines — it reflects the nature of obesity as a chronic, relapsing condition.” He added that the findings should serve as a cautionary note for short-term use without a more comprehensive weight management strategy.

Others in the health community are advocating for a holistic approach to prescribing these medications. Faye Riley, research communications lead at Diabetes UK, remarked, “Weight loss drugs can be effective tools for managing weight and type 2 diabetes risk — but this research reinforces that they are not a quick fix.” She stressed the importance of appropriate prescriptions paired with tailored support to help individuals maintain weight loss after discontinuing medication.

As the conversation around GLP-1 drugs evolves, the findings from this recent study underscore the necessity for a multifaceted approach to obesity management that extends beyond medications alone.